research use only
Cat.No.S7430
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Click to View More Cell Line Experimental Data | ||||||
| Molecular Weight | 306.40 | Formula | C15H14O3S2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 292605-14-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1C(S1)CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=CC=C3 | ||
|
In vitro |
DMSO
: 61 mg/mL
(199.08 mM)
Ethanol : 10 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
MMP-2
(Cell-free assay) 13.9 nM(Ki)
MMP-9
(Cell-free assay) 600 nM(Ki)
|
|---|---|
| In vitro |
SB-3CT directly inhibits bone marrow endothelial cell invasion and tubule formation in Matrigel in vitro. |
| Kinase Assay |
Fluorescence enzymatic activity assays
|
|
The enzymatic activity of MMP-2, MMP-9 and MMP-7 is monitored with the fluorescence quenched substrate MOCAcPLGLA2pr(Dnp)-AR-NH2. Fluorescence is measure with a PTI spectrofluorometer. The cuvette compartment is thermostated at 25 ℃ 。
|
|
| In vivo |
In L-CI.5s T-cell lymphoma model, SB-3CT (5-50 mg/kg/d i.p.) potently inhibit liver metastasis and increases survival of mice. This compound (50 mg/kg/d i.p.) inhibits human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model. In a mouse model of embolus-induced “permanent” focal cerebral ischemia, this chemical counteracts degradation of neuronal laminin, protects neurons from ischemic cell death, and ameliorates neurobehavioral outcomes after embolic MCA occlusion. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | Claudin11 / Occludin / ZO1 / Laminin-γ3 / β1-integrin |
|
19828778 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.